肝癌切除术辅以DC-CIK细胞治疗原发性肝癌的安全性及可行性分析

Safety and Feasibility of Hepatectomy for Liver Cancer Supplemented by DC-CIK Cells in Treatment of Primary Liver Cancer

目的探讨分析肝癌切除术辅以DC-CIK细胞治疗原发性肝癌的安全性及可行性。方法该研究患者整群选自2012年2月—2013年2月收治的82例原发性肝癌患者,分为观察组和对照组,每组41例,分别给予两组患者肝癌切除术辅以DC/CIK细胞治疗和单纯肝癌切除术,对比两组治疗情况。结果两组治疗后生存率、生活质量改善情况等对比差异无统计学意义(P>0.05)。观察组在DC-CIK治疗中有3例出现低烧且低温不超过38.5°,占7.31%,有1例出现轻度过敏反应,经对症治疗后均恢复正常。结论肝癌切除术辅以DC-CIK细胞治疗原发性肝癌能有效延长患者生存率,提高患者生活质量,安全性较高,值得临床推广和应用。

Objective To discuss and analyze the safety and feasibility of hepatectomy for liver cancer supplemented by DC-CIK cells in treatment of primary liver cancer. Methods 82 cases of patients with primary liver cancer admitted and treated from February 2012 to February 2013 were selected and divided into two groups with 41 cases in each, the observation group were treated with hepatectomy for liver cancer supplemented by DC-CIK cells, the control group were treated with simple hepatectomy for liver cancer, and the treatment conditions were compared between the two groups. Results There was no significance in the survival rate and improvement of quality of life between the two groups after treatment, P〉0.05, the low fever and low temperature not more than 38.5° occurred to 3 cases, accounting for 7.31% in the observation group, mild anaphylactic reaction occurred to 1 case, and all were back to normal after symptomatic treatment. Conclusion The hepatectomy for liver cancer supplemented by DC-CIK cells in treatment of primary liver cancer can effectively prolong the survival time and improve the quality of life of patients with high safety, which is worth clinical promotion and application.